Navigation Links
Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference

PARSIPPANY, N.J., Feb. 27, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro , Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Barclays 2013 Global Healthcare Conference on Tuesday, March 12, 2013 at 10:15AM ET at The Loews Miami Hotel in Miami, Florida. The presentation will be webcast live and can be accessed on Actavis' Investor Relations Web site at  The webcast can also be accessed at the following URL:

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Actavis, Inc.Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

Actavis is the world's third-largest generics prescription drug manufacturer.  Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.  The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.   Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. 

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually.  Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: )

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
2. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
3. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
4. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
5. MEI Pharma To Present At Cowen And Company Health Care Conference
6. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
7. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Isis Pharmaceuticals To Present At The Cowen and Company 33rd Annual Health Care Conference
9. Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
10. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
11. Zimmer Holdings to Present at Barclays Capital 2013 Global Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... LONDON , November 25, 2015 Developmental, ... key role in boosting the profitability of pharmaceutical products, ... Developmental, commercial, and regulatory/legal strategies all play ... says GBI Research . --> ... all play a key role in boosting the profitability of pharmaceutical ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
Breaking Medicine News(10 mins):